Loading...

Respiratory Disease

The treatment and management of respiratory disease continue to rapidly advance. In the past five years alone, we have seen the introduction of new and generic inhaled fixed dose combination products in asthma and COPD, new biologic options in asthma, the first disease-specific products in IPF and novel modes of action in PAH. Differences in dosing frequency and delivery devices add to the options now available to physicians and their patients. In an increasingly crowded market, new entrants find themselves competing with established standards of care. At the same time, new clinical data challenges the current recommended treatment approaches and continues to divide physician opinion.

Endotyping according to specific biomarkers has seen biologic therapy taking hold in severe asthma and trials are also being conducted in COPD, IPF and Nasal Polyps as pharma-companies seek to extend their indications. This true personalization of medicine will only continue to become more precise as new biomarkers are discovered and understood.

The Respiratory set of Disease Specific Programmes™ are designed to capture the impact of these changes in terms of mapping the treatment landscape, understanding changing physician opinion and alignment with guidelines, and identifying areas of continued unmet need. Importantly, they continue to provide evidence to support the medical community in understanding respiratory disease in real-world populations. To date, Respiratory DSP data has yielded over 100 publications and is referenced in the preface of the 2017 GOLD Strategy document.

Coronavirus (COVID-19)

As we deal with the current COVID-19 pandemic, we would like to assure you that Adelphi Group are taking every step to ensure the safety and wellbeing of all our staff, families, friends and communities. All staff worldwide are working from home and following individual Government Stay at Home guidelines to do all we can to Protect the Health Services and Save Lives. (UK : https://www.gov.uk/coronavirus) We will continue to exercise ‘Business as Usual’ to ensure our work for all continues. Indeed at the beginning of this month we held an extremely successful all work from home day to test our systems and ability to continue to communicate and deliver for whatever may happen in our world. Little did we know at the time how timely this was to be, and this will be an annual business continuity measure going forward. We would also like to share with you a programme ‘I AM PATIENT‘ produced by one of our Associate Companies, Snow, emphasising the importance of pro-actively following these critically important guidelines and to take personal responsibility to help stop the spread of this deadly virus https://www.youtube.com/watch?v=jZs-F2620CI #iampatient, #stayhome Stay Safe